JOHN EDWIN NESTLER
Medical Practice in Richmond, VA
License number
Pennsylvania MD028779E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Richmond, VA 23220
Pennsylvania
Pennsylvania
Personal information
See more information about JOHN EDWIN NESTLER at radaris.comName
Address
Phone
300 S Taylor St, Arlington, VA 22204
5800 Three Chopt Rd, Richmond, VA 23226
246 Woodridge Dr, Carnegie, PA 15106
202 Washington Ave, Clairton, PA 15025
2 Washington Ave, Clairton, PA 15025
Professional information
Dr. John E Nestler, Richmond VA - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism, Endocrinology & Metabolism
Address:
Richmond
1250 E Marshall St, Richmond 23298
(800) 762-6161 (Phone), (804) 828-5466 (Fax)
Pulmonary Dis & Crit Care Med
417 N 11Th St SUITE 4, Richmond 23298
(804) 828-2161 (Phone)
1250 E Marshall St, Richmond 23298
(800) 762-6161 (Phone), (804) 828-5466 (Fax)
Pulmonary Dis & Crit Care Med
417 N 11Th St SUITE 4, Richmond 23298
(804) 828-2161 (Phone)
Certifications:
Diabetes, Metabolism & Endocrinology, 1985, Internal Medicine, 1982
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Perelman School of Medicine University of Pennsylvania
Graduated: 1979
Virginia Commonwealth University Medical Center
University Of Pennsylvania
Perelman School of Medicine University of Pennsylvania
Graduated: 1979
Virginia Commonwealth University Medical Center
University Of Pennsylvania
Professor &Amp; Chair, Division Of Endocrinology And Metabolism At Virginia Commonwealth University
Location:
Richmond, Virginia Area
Industry:
Research
John E Nestler, Richmond VA
Specialties:
Endocrinologist
Address:
1250 E Marshall St, Richmond, VA 23298
Education:
University of Pennsylvania, Perelman School of Medicine - Doctor of Medicine
Hospital of the University of Pennsylvania - Fellowship - Endocrinology
Hospital of the University of Pennsylvania - Fellowship - Endocrinology
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Endocrinology and Metabolism (Internal Medicine)
John Nestler, Richmond VA
Work:
VCU Health System
417 N 11Th St, Richmond, VA 23298 Virginia Commonwealth University
1101 E Marshall St, Richmond, VA 23298 VCU Health System
1250 E Marshall St, Richmond, VA 23298
417 N 11Th St, Richmond, VA 23298 Virginia Commonwealth University
1101 E Marshall St, Richmond, VA 23298 VCU Health System
1250 E Marshall St, Richmond, VA 23298
Method Of Using Dehydroepiandrosterone And Dehydroepiandrosterone-Sulfate As Inhibitors Of Thrombuxane Production And Platelet Aggregation
US Patent:
5162198, Nov 10, 1992
Filed:
Sep 25, 1991
Appl. No.:
7/765368
Inventors:
David M. Eich - Richmond VA
Robert Jesse - Richmond VA
John Nestler - Richmond VA
Robert Jesse - Richmond VA
John Nestler - Richmond VA
Assignee:
Virginia Commonwealth University - Richmond VA
International Classification:
A01N 102, A61K 3156
US Classification:
435 2
Abstract:
Treating human beings with pharmacological quantities of DHEA results in their blood having increased serum DHEA and DHEA-S and lower rates of platelet aggregation. Reducing the rate of platelet aggregation can significantly reduce the incidence of morbidity and mortality from vascular events such as myocardial infarction and stroke, as well as reduce the occurrence of restenosis following vascular interventions. The concentration of DHEA and DHEA-S in the blood and the pre-incubation time of DHEA and DHEA-S with the blood will affect its impact on platelet aggregation. Hence, prior treatment of patients who are at risk with DHEA may produce the most beneficial affects. In addition, treatment of blood with DHEA-S reduces thromboxane production. Thromboxane is produced after platelets are subjected to many different types of agonists and is responsible for recruiting other platelets to aggregate and form a thrombus; therefore, blocking the production of thromboxane will reduce or prevent platelet aggregation.
Method Of Using Dehydroepiandrosterone And Dehydroepiandrosterone-Sulfate As Inhibitors Of Platelet Aggregation
US Patent:
5110810, May 5, 1992
Filed:
Feb 8, 1991
Appl. No.:
7/652518
Inventors:
David M. Eich - Suffolk VA
Robert Jesse - Richmond VA
John Nestler - Richmond VA
Robert Jesse - Richmond VA
John Nestler - Richmond VA
Assignee:
Virginia Commonwealth University - Richmond VA
International Classification:
A61K 3156
US Classification:
514178
Abstract:
Treating human beings with pharmacological quantities of DHEA results in their blood having increased serum DHEA and DHEA-S and lower rates of platelet aggregation. Reducing the rate of platelet aggregation can significantly reduce the incidence or morbidity and mortality from vascular events such as myocardial infarction and stroke, as well as reduce the occurrence of restenosis following vascular interventions. The concentration of DHEA and DHEA-S in the blood and the pre-incubation time of DHEA and DHEA-S with the blood will affect its impact on platelet aggregation. Hence, prior treatment of patients who are at risk with DHEA may produce the most beneficial affects. In addition, treatment of blood with DHEA-S reduces thromboxane production. Thromboxane is produced after platelets are subjected to many different types of agonists and is responsible for recruiting other platelets to aggregate and form a thrombus; therefore, blocking the production of thromboxane will reduce or prevent platelet aggregation.
Method Of Lowering Ldl Cholesterol In Blood
US Patent:
4920115, Apr 24, 1990
Filed:
Dec 28, 1988
Appl. No.:
7/291149
Inventors:
John E. Nestler - Richmond VA
Cornelius O. Barlascini - Columbus GA
John N. Clore - Richmond VA
William G. Blackard - Richmond VA
Cornelius O. Barlascini - Columbus GA
John N. Clore - Richmond VA
William G. Blackard - Richmond VA
Assignee:
Virginia Commonwealth University - Richmond VA
International Classification:
A61K 3156
US Classification:
514178
Abstract:
Therapeutic amounts of DHEA are administered to human patients for the treatment and prevention of such disorders as atherosclerosis, angina, diabetes, obesity and congestive heart failure. Administering therapeutic quantities of DHEA to human patients has been found to reduce body fat mass and increase muscle mass, lower serum LDL cholesterol levels, lower serum apoB levels, and not affect tissue sensitivity to insulin.